Advertisement
Supported by
The deal involves large pharmaceutical distributors and Teva, resolving cases that sought redress from the devastation caused by two decades of opioid abuse.
By Jan Hoffman
Facing multiple inquiries into its marketing practices and its role in the rise of teenage vaping, the company suspended internet access to mango, cucumber and other pods.
By Sheila Kaplan
The hospital group in California was accused of using its market dominance to demand higher prices for health care.
By Reed Abelson
Ms. Sackler’s was the matriarch of the company whose drug OxyContin has been blamed for the opioid epidemic.
By Sam Roberts
Azra Raza’s “The First Cell” poses hard questions about cancer treatment and end-of-life care.
By Henry Marsh
Robert Bilott was a corporate defense lawyer when a stranger shared a theory about why his cows were dying. “Exposure” is his story of what happened next.
By Gary Rivlin
Health officials say the flu season may complicate diagnosis of the lung damage from vaping, masking symptoms.
By Denise Grady
In a newly published guide, federal health officials say doctors “should never abandon” pain patients and warn of acute withdrawal and other risks.
By Abby Goodnough
The cause of the outbreak is still unknown, and the only advice health officials can offer so far is to avoid vaping.
A Philadelphia jury found that a subsidiary downplayed the risks that the anti-psychotic drug could lead to breast growth in boys.
By Mihir Zaveri and Katie Thomas
